Deramiocel BLA Amendment Buys Time, Not Validation: Approval Odds Remain Unfavorable

Capricor's Deramiocel Gains FDA Review Extension Potential

Capricor Therapeutics' shares surged by 68% following an announcement by CEO Linda Marbán that the FDA is open to reviewing an amendment to the Biologics License Application (BLA) for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel. This amendment will include 24-month open-label extension data from the HOPE-3 study and additional analyses, potentially leading to an extension of the PDUFA action date beyond the current August 22 deadline. This development offers a potential path forward after a contentious advisory committee meeting where the therapy was voted against.

• Capricor plans to submit an amendment to its BLA for deramiocel, incorporating 24-month open-label extension data from the HOPE-3 study and further analyses to support a refined indication. The FDA has indicated its willingness to review this submission and extend the PDUFA action date, providing renewed optimism for the Duchenne muscular dystrophy cell therapy.
• The FDA's previous advisory committee meeting resulted in a 9-3 vote against deramiocel's approval, primarily due to disagreements over statistical analysis and the agency's focus on cardiac function (a secondary endpoint) rather than the primary endpoint of upper limb performance, which Capricor maintains was met with statistical and clinical significance.
• Following the regulatory uncertainty, Capricor has put all other pipeline projects, including the StealthX exosome-based vaccine and another preclinical DMD candidate, on hold. The company reported $237.9 million cash on hand as of June 30, with a Q2 net loss of $40.7 million, and expects its cash runway to last at least twelve months, pending regulatory clarity.

Deramiocel's HOPE-3 Data: The Core of the Regulatory Debate

Recent clinical investigations in Duchenne muscular dystrophy (DMD) span a range of therapeutic modalities — from exon-skipping oligonucleotides and anti-inflammatory steroids to gene therapy — each with distinct efficacy signals and safety profiles. The studies below represent key data informing current regulatory and clinical discourse around DMD treatment.

Navigating DMD Endpoints: The Deramiocel Efficacy Controversy

Clinical trials in Duchenne muscular dystrophy (DMD) employ a range of functional, pulmonary, and biomarker endpoints to characterize disease progression and quantify treatment response across ambulatory and non-ambulatory patient populations. Ambulatory function is most commonly assessed using the North Star Ambulatory Assessment (NSAA), a disease-specific functional scale scored from 6 to 34, and the 6-minute walk test (6MWT), which captures walking distance within an observed range of 127 to 560.6 metres in ambulant patients. Timed functional tests complement these measures and include the 10-metre walk/run test (10MWR, ranging from 3 to 15 seconds), the 30-foot walk/run test, time to rise from floor (supine-to-stand, ranging from 1 to 27.5 seconds), and 4-stair climb velocity — collectively providing granular insight into functional decline over time.

Pulmonary and upper limb endpoints are particularly critical for non-ambulant patients, in whom lower limb assessments are no longer applicable. Dynamic pulmonary function tests — including forced vital capacity (FVC and FVC% predicted), forced expiratory volume in one second (FEV1 and FEV1% predicted), and peak expiratory flow (PEF and PEF% predicted) — are standard respiratory measures, alongside maximum static airway pressures such as maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP). Upper limb function is captured using the Performance of Upper Limb scale (PUL 1.2), which demonstrates an annual decline of approximately 4.13 points in non-ambulant cohorts, as well as MyoGrip and MyoPinch strength assessments, which show continuous deterioration independent of ambulatory status when expressed as percentage predicted.

Biomarker and composite endpoints round out the evidentiary framework used in DMD trials. Serum creatine kinase is employed as an exploratory outcome reflecting ongoing muscle damage, while dystrophin protein expression — quantified by Western blot and immunohistochemistry — serves as a surrogate or supportive biomarker in trials targeting the underlying genetic defect. Recognising the limitations of any single measurement domain in capturing yearly change, composite endpoints integrating respiratory, upper limb, and force measures have been developed to improve sensitivity for detecting clinically meaningful progression, particularly in patient subgroups where isolated domain assessments may lack sufficient responsiveness.

Deramiocel's Place in the Evolving DMD Treatment Landscape

The DMD treatment landscape has undergone substantial transformation over the past five years, driven by pivotal clinical trial data across three principal therapeutic modalities: antisense oligonucleotide (ASO)-based exon skipping, micro-dystrophin gene therapy, and dissociative corticosteroids. Among ASO therapies, four exon-skipping agents — eteplirsen, golodirsen, viltolarsen, and casimersen — have received FDA approval, each targeting distinct exon-skipping amenable mutations. Viltolarsen exemplifies the measurable but modest molecular gains achieved with this class: at doses of 40 and 80 mg/kg per week, mean dystrophin expression reached 5.7% and 5.9% of normal, respectively, accompanied by statistically significant improvements in timed function tests versus 65 age-matched natural history controls at week 25. While these agents demonstrate acceptable safety profiles, their limited dystrophin restoration has prompted investigation of next-generation ASOs incorporating novel chemical modifications and bioconjugations, with early clinical data suggesting improved molecular efficacy, though long-term safety comparability with first-generation compounds remains to be established.

Gene therapy has emerged as the most structurally transformative advance in the DMD pipeline. Delandistrogene moxeparvovec, now indicated for ambulatory pediatric patients aged 4–5 years with confirmed DMD gene mutations, has been evaluated in the phase 3 EMBARK trial (N = 125). Although the primary endpoint — change in North Star Ambulatory Assessment (NSAA) total score at 52 weeks versus placebo — did not achieve statistical significance, key secondary timed function endpoints suggested meaningful stabilization or slowing of disease progression. At the 104-week mark, EMBARK participants demonstrated statistically significant functional benefit versus an external control cohort across NSAA, Time to Rise, and 10-meter Walk/Run assessments, with sustained micro-dystrophin sarcolemmal expression and no new safety signals. Complementary data from a phase 1/2a trial of rAAVrh74.MHCK7.micro-dystrophin reported robust transgene expression in 81.2% of muscle fibers at 12 weeks, with a mean sarcolemmal intensity of 96%, and long-term follow-up from Study 101 demonstrated a mean 7.0-point increase in NSAA score from baseline to year 4, alongside a statistically significant 9.4-point advantage over a propensity-score-weighted external control cohort (P = .0125).

Vamorolone, a dissociative corticosteroid, has introduced a clinically meaningful safety differentiation from standard-of-care prednisone. In a pivotal 24-week randomised trial of 121 boys aged 4 to under 7 years, vamorolone at 6 mg/kg per day met its primary endpoint, demonstrating a statistically significant improvement in time-to-stand velocity versus placebo (0.05 m/s vs. −0.01 m/s; P = .002). Critically, prednisone-treated participants exhibited declines in height percentile and bone turnover markers, whereas vamorolone-treated patients did not — findings maintained and reinforced at 48 weeks, with prior prednisone-associated bone morbidities reversing upon transition to vamorolone. Notwithstanding these advances, important evidence gaps persist: post-approval efficacy data in real-world clinical practice remain limited, consensus-based frameworks for managing gene therapy-related adverse events (including acute liver injury, myocarditis, and immune-mediated myositis) are still nascent, and questions surrounding optimal treatment sequencing and combination strategies continue to require systematic investigation.

FDA's Open Door: A New Hope for Deramiocel in DMD

Duchenne muscular dystrophy (DMD) remains a devastating genetic disorder, progressively robbing patients of muscle function and ultimately leading to premature death, often due to cardiomyopathy. Against this backdrop, the recent announcement regarding Capricor Therapeutics' deramiocel offers a significant glimmer of hope, signaling a potential lifeline for a therapy that has already shown promise in clinical trials.

Deramiocel, an allogeneic cell therapy derived from cardiosphere-derived cells (CDCs), has demonstrated a unique dual impact, not only reducing the deterioration of upper limb function but also improving cardiac measures in late-stage DMD patients. This is particularly critical given the high incidence of cardiac complications in DMD. The underlying mechanism, involving potent anti-fibrotic and immunomodulatory effects, is further supported by a novel in vitro potency assay that directly correlates with clinical benefit, providing a robust scientific foundation for its therapeutic claims and ensuring manufacturing consistency.

However, the path forward is not without its challenges. While the FDA's willingness to review additional 24-month open-label extension data and analyses is a positive step, it follows a contentious advisory committee meeting where the therapy faced opposition. This underscores the need for the new data to definitively address previous concerns and demonstrate a clear, sustained benefit. Key risks to consider include:

• The inherent regulatory uncertainty, despite the positive signal from the FDA.

• The observed infusion-related hypersensitivity reactions, which, while manageable, require careful consideration for patient safety and long-term adherence.

• The need for robust, long-term data to confirm the durability of the therapeutic effect and its applicability across a broader patient population, given the relatively small sample size of the initial phase 2 study.

Ultimately, this development represents a critical juncture for deramiocel. If the additional data can successfully navigate the regulatory hurdles, it could establish a differentiated cell therapy that addresses both the skeletal and cardiac manifestations of DMD, offering a much-needed new option for patients and their families.